Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, November 9, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Kyle Rose Downgraded (BVS) to Hold on, Nov 9th, 2022
Kyle Rose of Canaccord Genuity, Downgraded "Bioventus Inc." (BVS) to Hold on, Nov 9th, 2022.
Kyle has made no other calls on BVS in the last 4 months.
There are 2 other peers that have a rating on BVS. Out of the 2 peers that are also analyzing BVS, 1 agrees with Kyle's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $13 on, Wednesday, September 7th, 2022
This is the rating of the analyst that currently disagrees with Kyle
- Drew Ranieri of "Morgan Stanley" Maintained at Buy with Decreased Target to $11 on, Tuesday, October 11th, 2022
